Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS‐LED trial)
DiscussionAdministration of human choriogonadotropin alfa followed by erythropoietin is safe after a new ischemic stroke. At the doses studied, placebo and active groups did not differ significantly in neurological recovery. Study limitations, such as the use of multiple assessors, differences in rehabilitation care, and being underpowered to show efficacy, are discussed. (Source: International Journal of Stroke)
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Steven C. Cramer, Michael D. Hill, Tags: Research Source Type: research
Biosimilar competition: lessons from Europe
Nature Reviews Drug Discovery 13, 99 (2014).
doi:10.1038/nrd4210
Authors: Henry Grabowski, Rahul Guha & Maria Salgado
Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 21, 2014 Category: Drugs & Pharmacology Authors: Henry GrabowskiRahul GuhaMaria Salgado Tags: News and Analysis Source Type: research
Successful surgical repair of acute type A aortic dissection without the use of blood products.
We report successful surgical treatment of type A aortic dissection in a Jehovah's Witness without the use of any blood products. An interposition graft replacement of the ascending aorta was carried out. This was under right axillo-atrial cardiopulmonary bypass with antegrade cerebral perfusion via right a subclavian and left carotid cannula for 24 minutes at 28°C. Body temperature was kept at 32°C throughout. Autologous transfusion was deployed using cell salvage and a preoperative haemodilution technique. The patient was given tranexamic acid, desmopressin, recombinant factor VIIa, folic acid and epoetin alfa. Patient...
Source: Annals of the Royal College of Surgeons of England - October 1, 2013 Category: Surgery Authors: Papalexopoulou N, Attia RQ, Bapat VN Tags: Ann R Coll Surg Engl Source Type: research
Hickam's Dictum in a Patient With Diarrhea
Question: A 49-year-old woman with a history of 2 cadaveric renal transplants was referred for colonoscopy for evaluation of 4 weeks of bloody diarrhea with associated crampy abdominal pain. Renal transplants occurred in 1998 and 2005 for end-stage renal disease related to glomerulonephritis and subsequent chronic allograft nephropathy. Other past medical history was notable for recurrent urinary tract infections with bilateral ureteral stents placed 6 months ago, immune thrombocytopenic purpura, and hypertension. Her medications at the time of colonoscopy were mycophenolate mofetil, prednisone, valacyclovir, romiplostim, ...
Source: Gastroenterology - September 25, 2013 Category: Gastroenterology Authors: Joseph D. Feuerstien, Robert Najarian, Adam S. Cheifetz Tags: Clinical Challenges and Images in GI Source Type: research
Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.
Conclusions: Once-monthly CERA administered to CKD-5D patients was associated with negligible changes in mean Hb option for these patients.
PMID: 24052462 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)
Source: Journal of Nephrology - September 13, 2013 Category: Urology & Nephrology Authors: Locatelli F, Mandolfo S, Menegato Adorati M, Villa G, Tarchini R, Pizzarelli F, Conte F, Guastoni C, Ricciardi B, Crotta A Tags: J Nephrol Source Type: research
Administration of low dose epoetin alfa facilitates adherence to ribavirin in triple therapy with PEG‐IFN‐alfa2b and telaprevir
ConclusionEPO can be a favorable alternative to reduction of RBV to facilitate the adherence of patients on TVR‐based triple therapy. (Source: Hepatology Research)
Source: Hepatology Research - August 19, 2013 Category: Internal Medicine Authors: Hisashi Ishida, Sadatsugu Sakane, Takashi Toyama, Keisuke Fukutomi, Keiichi Kimura, Aya Sugimoto, Kenji Hibino, Takeshi Tamura, Tetsuya Iwasaki, Ryuichiro Iwasaki, Hiroko Hasegawa, Yuko Sakakibara, Takuya Yamada, Shoichi Nakazuru, Eiji Mita Tags: Original Article Source Type: research
Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
Conclusions
Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival. However, epoetin alfa had an adverse effect, resulting in increased thrombosis. (Source: JNCI)
Source: JNCI - July 16, 2013 Category: Cancer & Oncology Authors: Moebus, V., Jackisch, C., Schneeweiss, A., Huober, J., Lueck, H.-J., du Bois, A., Thomssen, C., Kurbacher, C., Kuhn, W., Nitz, U., Runnebaum, I. B., Hinke, A., Kreienberg, R., Untch, M., on behalf of the AGO Breast Study Group Tags: Article Source Type: research
Epoetin Alfa: To Give or Not to Give
(Source: JNCI)
Source: JNCI - July 16, 2013 Category: Cancer & Oncology Authors: Dang, C., Hudis, C., Norton, L. Tags: Solicited Editorial Source Type: research
Epoetin alfa reduces anemia in breast cancer patients with no negative impact on survival
(Source: JNCI)
Source: JNCI - July 16, 2013 Category: Cancer & Oncology Tags: Memo to the Media Source Type: research
TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients
Abstract
Clinical guidelines recommend concurrent treatment of anemia in end‐stage renal disease with erythropoiesis‐stimulating agents (ESAs) and iron. However, there are mixed data about optimal iron supplementation. To help address this gap, the relationship between iron markers and hemoglobin (Hb) response to ESA (Epoetin alfa) dose was examined. Electronic medical records of 1902 US chronic hemodialysis patients were analyzed over a 12‐month period between June 2009 and June 2010. The analysis included patients who had at least one Hb value during each 4‐week interval for four consecutive intervals (k − ...
Source: Hemodialysis International - July 1, 2013 Category: Hematology Authors: Adam E. Gaweda, Premila Bhat, Gregory A. Maglinte, Chun‐Lan Chang, Jerrold Hill, Grace S. Park, Akhtar Ashfaq, Matthew Gitlin Tags: Original Article Source Type: research
Anaemia in CKD 5D
Conclusions:After conversion from stable epoetin, >75% of peginesatide pts achieved initial dose stability within 1–2 doses. Compared with pts who remained on epoetin, peginesatide pts did not differ in achievement of dose stability. These post-hoc results may warrant further study. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Mikhail, A., Kaplan, M., Macdougall, I., Schmidt, R. J., Rastogi, A., Wang, W., Tong, S., Mayo, M., Oestreicher, N., Schiller, B., Green, J. M., Verma, R., Leu, K., Mortensen, R. B., Young, P. R., Schatz, P., Wojchowski, D. M., Shimonaka, Y., Sasaki, Y., Tags: Abstracts Source Type: research
Impact of Epoetin Alfa on Left Ventricular Structure, Function, and Pressure Volume Relations as Assessed by Cardiac Magnetic Resonance: The Heart Failure Preserved Ejection Fraction (HFPEF) Anemia Trial.
Abstract
Anemia, a common comorbidity in older adults with heart failure and a preserved ejection fraction (HFPEF), is associated with worse outcomes. The authors quantified the effect of anemia treatment on left ventricular (LV) structure and function as measured by cardiac magnetic resonance (CMR) imaging. A prospective, randomized single-blind clinical trial (NCT NCT00286182) comparing the safety and efficacy of epoetin alfa vs placebo for 24 weeks in which a subgroup (n=22) had cardiac magnetic resonance imaging (MRI) at baseline and after 3 and 6 months to evaluate changes in cardiac structure and f...
Source: Congestive Heart Failure - March 20, 2013 Category: Cardiology Authors: Green P, Babu BA, Teruya S, Helmke S, Prince M, Maurer MS Tags: Congest Heart Fail Source Type: research
Treating Anemia in Older Adults With Heart Failure With a Preserved Ejection Fraction With Epoetin Alfa: Single-blind Randomized Clinical Trial of Safety and Efficacy [Original Articles]
Conclusions—
Administration of epoetin alfa to older adult patients with heart failure and a preserved ejection fraction compared with placebo did not change left ventricular end-diastolic volume and left ventricular mass nor did it improve submaximal exercise capacity or quality of life.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00286182. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - March 19, 2013 Category: Cardiology Authors: Maurer, M. S., Teruya, S., Chakraborty, B., Helmke, S., Mancini, D. Tags: Other heart failure, Remodeling, Other Treatment Original Articles Source Type: research
